Vanguard Group Inc Eye Point Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,803,227 shares of EYPT stock, worth $23.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,803,227
Previous 3,048,182
24.77%
Holding current value
$23.8 Million
Previous $24.4 Million
16.34%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding EYPT
# of Institutions
152Shares Held
59.5MCall Options Held
177KPut Options Held
263K-
Cormorant Asset Management, LP Boston, MA8.33MShares$52.2 Million4.66% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.18MShares$32.5 Million1.63% of portfolio
-
Franklin Resources Inc San Mateo, CA4.01MShares$25.2 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.79MShares$23.8 Million0.06% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$23.6 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $214M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...